Undernutrition
Conditions
Brief summary
The purpose of this study was to determine the improvement in nutritional status, especially in the level of insulin-like growth factor-1 (IGF-1) and its relationship with changes in the circulating cytokine levels, after providing extra protein and energy contents to community-dwelling older adults at risk of undernutrition.
Detailed description
Sixty of aged over 65 years, living independently in the community for elderly people, nondiabetic subjects with serum prealbumin of under 30 mg/dL and BMI under 25 kg/m2 were recruited. The subjects were followed for a 2-week pre-intervention period, followed by an intervention period, which they received 2 cartons of liquid oral nutritional supplementation daily for 2 weeks.
Interventions
DIETARY_SUPPLEMENTPre-intervention
First 2-weeks : keeping routine dietary habit
DIETARY_SUPPLEMENTLiquid nutritional supplement
Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
Sponsors
Yonsei University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to 86 Years
Healthy volunteers
No
Inclusion criteria
* voluntarily agree to participate and sign in informed consent form * aged 65 years or older * a serum prealbumin level≤30 mg/dL and a BMI\<25 kg/m2
Exclusion criteria
* inability to perform oral ingestion * known allergies to milk or eggs * an inability to communicate, such as those with Alzheimer's disease * malabsorption syndrome, a history of gastrectomy or enterectomy * diabetes, liver disease, renal disease, neurological disease, pancreatitis, malignancy, cardiovascular or cerebrovascular disease, metabolic syndrome * any other disease requiring treatment, medication or alcohol abuse * any condition that the investigator believes may put the subjects at under risk
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prealbumin (mg/dL) | at pre-treatment (week -2) |
| Transferrin (mg/dL) | at pre-treatment (week -2) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum albumin (g/dL) | 4 weeks | 3 times during 4 weeks : at pre-treatment (week -2) / at baseline (week 0) / at post-treatment (week 2) |
| Weight (kg) | 4 weeks | 3 times during 4 weeks : at pre-treatment (week -2) / at baseline (week 0) / at post-treatment (week 2) |
| Osmolality (mOsm/kgH2O) | 4 weeks | 3 times during 4 weeks : at pre-treatment (week -2) / at baseline (week 0) / at post-treatment (week 2) |
| Insulin growth factor-1 (ng/mL) | 4 weeks | 3 times during 4 weeks : at pre-treatment (week -2) / at baseline (week 0) / at post-treatment (week 2) |
| Body mass index (kg/m2) | 4 weeks | 3 times during 4 weeks : at pre-treatment (week -2) / at baseline (week 0) / at post-treatment (week 2) |
Outcome results
None listed